

Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer – A case report from a tertiary cancer center

Aswin Nagarajan, Arun Sakthivelu, Narendran Santhanaraman, Ramya Ravichandar

Corresponding author

Aswin Nagarajan

*Department of Radiation Oncology, Cancer institute, 38, Sardar Patel road, Adyar, Chennai
– 600020, Tamil Nadu, India*

Handling editor:

Michal Heger

Department of Pharmaceutics, Utrecht University, the Netherlands

Department of Pharmaceutics, Jiaying University Medical College, Zhejiang, China

Review timeline:

Received: 09 August, 2020
Editorial decision: 26 January, 2021
Revision received: 2 February, 2021
Editorial decision: 5 February, 2021
Revision received: 9 February, 2021
Editorial decision: 28 February, 2021
Revision received: 20 March, 2021
Editorial decision: 24 March, 2021
Published online: 16 April, 2021

1st Editorial decision
26-Jan-2021

Ref.: Ms. No. JCTRes-D-20-00079

**NIMOTUZUMAB COMBINED WITH RADIOTHERAPY FOR THE TREATMENT OF
HYPOPHARYNGEAL CANCER – A CASE REPORT FROM A TERTIARY CANCER
CENTRE.**

Journal of Clinical and Translational Research

Dear Dr. Nagarajan,

Reviewers have now commented on your paper. You will see that they are advising that you revise your manuscript. If you are prepared to undertake the work required, I would be pleased to reconsider my decision.

For your guidance, reviewers' comments are appended below.

If you decide to revise the work, please submit a list of changes or a rebuttal against each point which is being raised when you submit the revised manuscript. Also, please ensure that the track changes function is switched on when implementing the revisions. This enables the reviewers to rapidly verify all changes made.

Your revision is due by Feb 25, 2021.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Reviewers' comments:

Reviewer #2: DETAILS OF TREATMENT REQUIRED , CHEMO DOSE , RT DOSE AND EQPT USED.

Authors' response

Reviewers' comments:

Reviewer #2: DETAILS OF TREATMENT REQUIRED , CHEMO DOSE , RT DOSE AND EQPT USED.

We are grateful for your commentary and suggestions, which we have addressed to the fullest extent as indicated below for your comments

CASE REPORT (Page no 4, line no 6,7,8 – highlighted in yellow)

The patient received radiotherapy to a total dose of 66Gy(200cGy/fraction up to 33fractions) using conformal technique(Varian Linear Accelerator) along with 5 cycles of weekly nimotuzumab (200mg)

2nd Editorial decision
05-Feb-2021

Ref.: Ms. No. JCTRes-D-20-00079R1
NIMOTUZUMAB COMBINED WITH RADIO THERAPY FOR THE TREATMENT OF HYPOPHARYNGEAL CANCER – A CASE REPORT FROM A TERTIARY CANCER CENTRE.

Journal of Clinical and Translational Research

Dear author(s),

Reviewers have submitted their critical appraisal of your paper. The reviewers' comments are appended below. Based on their comments and evaluation by the editorial board, your work was FOUND SUITABLE FOR PUBLICATION AFTER MINOR REVISION.

If you decide to revise the work, please itemize the reviewers' comments and provide a point-by-point response to every comment. An exemplary rebuttal letter can be found on at <http://www.jctres.com/en/author-guidelines/> under "Manuscript preparation." Also, please use the track changes function in the original document so that the reviewers can easily verify

your responses.

Your revision is due by Mar 07, 2021.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely,

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Reviewers' comments:

Dear Dr. Nagarajan,

Thank you for resubmitting your revision.

I have gone through your manuscript and in my view the external review process is now completed.

However, your manuscript is replete with grammar and spelling errors and this needs to be corrected before we can proceed to publication. Please do not take this request lightly; I am what some call a spelling Nazi and do not tolerate sloppiness too well. It is better for your health to do a perfect job in one go rather than having us going back and forth until your paper meets the journal's explicit guidelines.

Thanks in advance for raising the level of your text to academic English.

Michal Heger
Editor

Authors' response

We are grateful for your commentary and suggestions, which we have addressed to the fullest extent as indicated below for your comments

The grammar and the spelling errors are corrected as per your advice and are highlighted in green color in the manuscript.

ABSTRACT: Lines 2,4,6

INTRODUCTION: Lines 13,16,21,24,25,27,29,31,33

CASE REPORT: Lines 1,3,10,11,12,13,15,16,19,22,24

DISCUSSION: Lines 1,2,3,7,21,26.

CONCLUSION: Line 2

3rd Editorial decision
24-Mar-2021

Ref.: Ms. No. JCTRes-D-20-00079R3

**NIMOTUZUMAB COMBINED WITH RADIOTHERAPY FOR THE TREATMENT OF
HYPOPHARYNGEAL CANCER – A CASE REPORT FROM A TERTIARY CANCER
CENTRE.**

Journal of Clinical and Translational Research

Dear authors,

I am pleased to inform you that your manuscript has been accepted for publication in the Journal of Clinical and Translational Research.

You will receive the proofs of your article shortly, which we kindly ask you to thoroughly review for any errors.

Thank you for submitting your work to JCTR.

Kindest regards,

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Comments from the editors and reviewers: